Bioassociate Consulting

Long/short equity, value, event-driven, long only
Bioassociate Consulting
Long/short equity, value, event-driven, long only
Contributor since: 2012
Company: Bioassociate
Tonix's Clinical-Stage Drug, TNX-102SL, Is Completely Unneeded
InterMune Is Set To Outperform Its Main Competitor
Grim Near-Term Prospects For Zogenix
Undervalued Biotech Stocks In Non-U.S. Markets: Part 1